Risankizumab shows high efficacy and maintenance in improvement of response until week 52-Reference-Cited by-同舟云学术

Risankizumab shows high efficacy and maintenance in improvement of response until week 52

Published:2022-02-28 Issue:5 Volume:35 Page:
ISSN:1396-0296
Container-title:Dermatologic Therapy
language:en
Short-container-title:Dermatologic Therapy

Author:

Mastorino Luca¹^ORCID,Susca Sara¹,Megna Matteo²,Siliquini Niccolò¹^ORCID,Quaglino Pietro¹,Ortoncelli Michela¹,Avallone Gianluca¹,Rubatto Marco¹,Fabbrocini Gabriella²^ORCID,Dapavo Paolo¹,Ribero Simone¹^ORCID

Affiliation:

1. Department of Medical Sciences, Section of Dermatology University of Turin Torino Italy

2. Section of Dermatology, Department of Clinical Medicine and Surgery University of Naples Federico II Naples Italy

Publisher

Hindawi Limited

Subject

Dermatology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dth.15378

Reference25 articles.

1. Efficacy, safety, and drug survival of IL-23, IL-17, and TNF-alpha inhibitors for psoriasis treatment: a retrospective study

2. Risankizumab for the Treatment of Moderate-to-Severe Psoriasis: Real-Life Multicenter Experience from the Czech Republic

3. Risankizumab in real life: preliminary results of efficacy and safety in psoriasis during a 16-week period

4. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials

5. Efficacy and safety of risankizumab vs. secukinumab in patients with moderate‐to‐severe plaque psoriasis (IMMerge): results from a phase III, randomized, open‐label, efficacy–assessor‐blinded clinical trial*

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical efficacy of risankizumab in patients with psoriasis: A Japanese case series;JAAD International;2024-09

2. Clinical Characteristics Associated With Response to Biologics in the Treatment of Psoriasis;JAMA Dermatology;2024-08-01

3. Psoriasis With Leg Involvement, a New Difficult-to-Treat Area: A Cohort Study of Patients Treated With Risankizumab;Dermatology Practical & Conceptual;2024-07-31

4. Factors Associated With Achieving Complete Skin Clearance Compared to Almost Complete Skin Clearance in Patients With Moderate to Severe Psoriasis Treated With Biologics: A Retrospective Chart Review;Annals of Dermatology;2024

5. Predictors for the effectiveness of 75 mg risankizumab in treating psoriasis—A real‐word evidence from a 52‐week retrospective study;Experimental Dermatology;2023-10-21